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Synovial biomarkers have recently been adopted as diagnostic tools for prosthetic 
joint infection (PJI) but their utility is uncertain. The purpose of this systematic 
review and meta-analysis was to synthesise the evidence on the accuracy of alpha-
defensin immune-assay and leucocyte esterase colorimetric test strip for the diagnosis 
of PJI, compared to the Musculoskeletal Infection Society diagnostic criteria. 
Methods: 
We performed a systematic review to identify diagnostic technique studies evaluating 
the accuracy of alpha-defensin or leukocyte esterase in the diagnosis of PJI. OVID 
MEDLINE, EMBASE, ACM, ADS, arXiv, CERN DS, Crossref DOI, DBLP, 
Espacenet, Google Scholar, Gutenberg, Highwire, IEEExplore, Inspire, JSTOR, 
OAlster, Open Content, Pubget, PubMed and Web of Science entries for the last 10 
years were searched along with grey literature. Classification of studies and data 
extraction were performed independently by two reviewers. Data extraction permitted 
meta-analysis of sensitivity, specificity with construction of receiver operator 
characteristic curves for each test. 
Results: 
We included 11 eligible studies. The pooled diagnostic sensitivity and specificity of 
alpha-defensin (six studies) for PJI were 1.00 (95% CI 0.82-1.00) and 0.96 (95% CI 
0.89-0.99) respectively. The Area Under the Curve (AUC) for alpha-defensin and PJI 
was 0.99 (95% CI 0.98-1.00). The pooled diagnostic sensitivity and specificity of 
leucocyte esterase (five studies) for PJI were 0.81 (95% CI 0.49-0.95) and 0.97 (95% 
CI 0.82-0.99) respectively. The AUC for leucocyte esterase and PJI was 0.97 (95% CI 
0.95-0.98) There was substantial heterogeneity between studies for both diagnostic 
tests. 
Conclusions: 
The diagnostic accuracy for PJI was high for both tests. Given the limited number of 
studies, more independent research on these tests is warranted given the large cost 
difference between the tests. 
 Level of Evidence: 




Periprosthetic joint infection (PJI) is a rare complication affecting between 0.7 and 
2.4% of patients receiving joint arthroplasty1-9. PJI after hip and knee arthroplasty in 
particular has extremely negative effects on physical, emotional, social and economic 
aspects of a patient’s life10. Early diagnosis can lead to less radical treatment with 
debridement and retention of prostheses instead of one or two-stage revision. 
Establishing a diagnosis of infection promptly11 is therefore of paramount importance, 
yet may be very challenging as the classic clinical features may be absent and a 
painful joint replacement may be caused by other pathologies. The Musculoskeletal 
Infection Society (MSIS) has developed diagnostic criteria to standardize and 
facilitate this diagnostic process (Table 1)12. The search for a single diagnostic test 
with the requisite accuracy, sensitivity and specificity has yielded numerous 
biomarkers as potential candidates – the term biomarker meaning a biologically 
pertinent molecule that can be evaluated objectively to indicate the presence of a 
disease or biological state. Alpha-defensin13 and leucocyte esterase14 are currently 
among the most promising. 
Alpha-defensin is an antimicrobial peptide that is released naturally from activated 
neutrophils. The peptide then integrates into, and destroys, the pathogens cell 
membrane15. The alpha-defensin immunoassay was developed from both genomic 
and proteomic studies and provides a qualitative result specific for synovial fluid. The 
advantages of this test include its simplicity and standardization whilst a disadvantage 
is its relatively high cost of £500 per test ($760 US) (Synovasure, Zimmer). 
Leucocyte esterase is an enzyme secreted by activated neutrophils recruited to areas 
of infection. Detection of leucocyte esterase has been used for many years in 
urinalysis to diagnose urinary infection16. The leucocyte esterase colormetric strip test 
is performed by applying fluid to a reagent test strip. A detergent on the strip lyses the 
neutrophils within the fluid and this releases esterase which catalyses a reaction 
leading to formation of a violet dye. Advantages of this test are that it is quick, easy 
and inexpensive at 11 pence (17 cents US) per test (Combur-7, Roche). A potential 
disadvantage is the invalidation of the result by blood contamination17 although this 
has been addressed by centrifugation prior to application of the fluid18. Both of the 
tests describe require a synovial fluid sample. 
The purpose of this systematic review and meta-analysis was to synthesise the 
available evidence on the accuracy of alpha-defensin and leucocyte esterase in the 
diagnosis of PJI. 
  
Materials and Methods: 
We used a rigorous and systematic approach conforming to the Preferred Reporting 
Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines19 (Appendix) 
and the critical evaluation of studies relating to diagnosis of PJI20. 
Protocol 
A protocol was registered online with PROSPERO (CRD42015023704) before 
commencing the review as recommended by PRISMA. 
Search strategy 
We searched all studies indexed in MEDLINE and Embase on the Ovid platform, 
ACM, ADS, arXiv, CERN DS, Crossref DOI, DBLP, Espacenet, Google Scholar, 
Gutenberg, Highwire, IEEExplore, Inspire, JSTOR, OAlster, Open Content, Pubget, 
PubMed and Web of Science from 1st June 2005 until 30th May 2015 years using the 
search strategy shown as applied in MEDLINE and Embase in Table 2. We also 
evaluated the grey literature with hand searches of six major Orthopaedic journals 
over the last five years. The bibliographies of the relevant articles were then cross-
checked for articles not identified in the search. Studies in patients of all age groups 
were included. No language restrictions were applied, which is an important 
consideration with the perceived international interest in treatment of infected hip 
prostheses. The screening of studies was performed by two independent assessors 
with any disagreements resolved by a third reviewer. An Excel spreadsheet was 
constructed to summarise the findings of relevant studies. 
Eligibility criteria 
We included all diagnostic studies that enrolled patients with true diagnostic 
uncertainty in the setting of PJI. Tests of interest were alpha-defensin assay and 
leucocyte esterase test scoring ++. Eligible studies had a reference standard for 
diagnosing prosthetic joint infection using the MSIS diagnostic criteria.  
Screening 
A total of 1,796 records were identified from searching the literature. The titles and 
abstracts were screened to identify potentially useful articles for inclusion in this 
systematic review. After screening, 30 full articles were assessed in detail for 
eligibility against criteria. A PRISMA flow diagram of the progression of studies 
through this systematic review is provided in Figure 2. 
Data extraction 
Two of the authors (MCW and SKK) worked independently to extract the data using 
standardized forms. We extracted data on sensitivity, specificity, likelihood ratio’s, 
participants, joint involved, diagnostic test performed, cut off or range definitions of 
the tests, whether the cut-offs were derived with the use of receiver operator 
characteristic curves or predetermined by the study authors plus the nature and 
characteristics of the reference standard test. Quality assessment of each study was 
also performed using the QUADAS-2 tool21. 
Statistical analyses 
Overall sensitivity and specificity values for the diagnosis of PJI were pooled using 
the bivariate meta-analysis framework22. The bivariate model is an improvement and 
extension of the traditional summary receiver operating characteristic (sROC) and 
jointly models sensitivity and specificity as the starting point of the analysis and 
hence may be more reliable for estimating diagnostic accuracy23, 24. The sROC curve 
shows the consistency of results across studies and therefore whether there was a 
uniform Receiver Operator Curve (ROC) curve over all studies. The sROC curve 
data-points come from regression analysis of each study whilst the ROC curve data-
points come from each threshold. In addition the area under the curve (AUC) depicts 
the accuracy of the test. The bivariate model employs a random effects approach, 
which takes into account the heterogeneity beyond chance between studies. In 
addition, it also accounts for between-study correlation between underlying sensitivity 
and specificity, caused by the use of different thresholds across studies. I2 was used to 
assess inconsistency between studies. An I2 statistic is the proportion of variability 
across studies due to patient population variability rather than to sampling error. I2 lies 
between 0% and 100%. A value of 0% indicates no observed heterogeneity, and 
values greater than 50% may be considered substantial heterogeneity A priori 
hypotheses to explain potential heterogeneity included site of the prosthesis and 
diagnosis of infection occurring at different time points. 
Pooled positive and negative likelihood ratios were calculated using the summary 
estimates of sensitivity and specificity. Potential sources of heterogeneity across 
studies could not be investigated because of the limited number of studies. In addition, 
tests for publication bias (e.g. Egger’s test) require at least 10 studies and lower 
heterogeneity to be useful and valid, therefore we were unable to investigate for 
publication bias.  All analyses were conducted using Stata version 14 (Stata Corp, 
College Station, Texas) and the –midas- and –metandi- commands were used for all 
analyses. 
Sources of funding 
This article presents independent research funded by the National Institute for Health 
Research (NIHR) under its Programme Grants for Applied Research programme (RP-
PG-1210-12005). The views expressed in this article are those of the authors and not 
necessarily those of the NHS, the NIHR or the Department of Health.  
  
Results: 
There were 10 articles reporting 11 evaluations13, 14, 17, 18, 25-30 contributing to our 
estimates of diagnostic accuracy for both tests. Six studies explored the diagnostic 
accuracy of alpha-defensin for PJI13, 17, 25-27, 30, while the remaining five studies 
explored the diagnostic accuracy of leucocyte esterase for PJI14, 17, 18, 28, 29. Study 
characteristics are summarised in Table 3. All of the included studies were published 
within the last five years and originated from the USA. The largest contribution for 
the alpha-defensin test was from Deirmengian and colleagues13, 17, 26, 30 but there was 
no overlap in patients within these studies. The total number of patients contributing 
to the meta-analyses of alpha-defensin and leucocyte esterase were 2,321 and 545 
respectively and involved 613 PJI's. 
Quality assessment 
In Table 4 the QUADAS-2 assessments for each study are reported. Using the 
QUADAS-2 tool those studies identified had a mean score of 13.3 (range 12 to 14) 
where a maximum score is 14. This indicates that the studies used in this meta-
analysis were of good quality. 
Diagnostic value of alpha-defensin for prosthetic joint infection 
The pooled diagnostic sensitivity and specificity of alpha-defensin for PJI were 1.00 
(95% CI: 0.82 to 1.00) and 0.96 (95% CI: 0.89 to 0.99) respectively (Figure 2). There 
was substantial heterogeneity between studies; I2 (95% CIs) for sensitivity and 
specificity values were 98.2 (95% CI: 97.5 to 98.9) and 98.8 (95% CI: 98.4 to 99.2) 
respectively. The pooled Positive Likelihood Ratio (PLR), Negative Likelihood Ratio 
(NLR), and diagnostic score were 27.0 (95% CI: 9.0 to 80.6), 0.00 (95% CI: 0.00 to 
0.22), and 8.94 (95% CI: 4.73 to 13.15) respectively. The AUC for alpha-defensin and 
PJI was 0.99 (95% CI: 0.98 to 1.00) (Figure 3).  
Diagnostic value of leucocyte esterase for prosthetic joint infection 
The pooled diagnostic sensitivity and specificity of leucocyte esterase for PJI were 
0.81 (95% CI: 0.49 to 0.95) and 0.97 (95% CI: 0.82 to 0.99) respectively (Figure 4). 
There was substantial heterogeneity between studies, I2 (95% CIs) for sensitivity and 
specificity values were 94.6 (95% CI: 91.4 to 97.9) and 93.3 (95% CI: 89.0 to 97.6) 
respectively. The pooled PLR, NLR, and diagnostic score were 23.9 (95% CI: 3.8 to 
152.1), 0.19 (95% CI: 0.06 to 0.66), and 4.82 (95% CI: 2.27 to 7.36) respectively. The 
AUC for leucocyte esterase and PJI was 0.97 (95% CI: 0.95 to 0.98) (Figure 5).  
  
Discussion: 
The prompt diagnosis of PJI remains a clinical challenge due to the diverse clinical 
presentations of patients suffering from this complication and the overlap of some of 
these features with other diagnoses and causes of failure of joint arthroplasty. The 
distinction between PJI and other causes of failure is important as the surgical 
management and chance of a successful outcome differs according to the mode of 
failure and thus the treatment strategy employed. 
This systematic review has shown that alpha-defensin is extremely sensitive and 
specific in identifying PJI and that leucocyte esterase is slightly less sensitive, but also 
extremely specific. Both are therefore good candidates for diagnostic biomarkers. 
Traditional tests to diagnose PJI are less effective. In a study examining diagnostic 
accuracy for inflammatory serological markers in PJI31 the pooled sensitivity and 
specificity for ESR were 88% (95% CI: 86% to 90%) and 70% (95% CI: 68% to 
72%) respectively. The pooled sensitivity and specificity for CRP were 97% (95% CI: 
93% to 99%) and specificity 91% (95% CI: 87% to 94%).  However this study did not 
use the MSIS criteria as its gold standard. 
The strengths and potential limitations of this analysis deserve mention. Our meta-
analysis is the first of its kind and it examined nearly two thousand patients in studies 
that were performed to a very high standard. All studies included in the review used 
the MSIS criteria, thereby minimising classification bias by using a common and 
widely accepted reference standard12. The studies in our meta-analysis examined a 
large spectrum of joint arthroplasty including shoulder, hip and knee replacements, 
suggesting that the findings of our study can be generalised to several clinical 
scenarios. A number of the studies on alpha-defensin came from the same research 
group, which is unsurprising given the relative novelty of the test. This could hamper 
the generalisation of our findings; however, these findings were replicated by other 
groups. The limited number of studies precluded the ability to explore for publication 
bias and potential sources of heterogeneity. None of the studies reported on blinding 
which potentially may have introduced selection bias. Further large-scale and rigorous 
studies are warranted to evaluate the use of these synovial markers as diagnostic tools 
for PJI.  
Alpha-defensin is substantially more expensive (£500 GBP per test) than leucocyte 
esterase (£0.11 GBP per test), but more specific in diagnosing PJI, it may be that they 
both have a clinical role as biomarkers.  We recommend that further comparisons are 
made between these two promising biomarkers and traditional diagnostic tests to 
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